ジソピラミド
J Am Coll Cardiol 45 (8): 1251–1258. (2005). doi:10.1016/j.jacc.2005.01.012. PMID 15837258.
↑ “Historical trends in reported survival rates in patients with hypertrophic cardiomyopathy”. Heart 92 (6): 785–791. (2006). doi:10.1136/hrt.2005.068577. PMC 1860645. PMID 16216855. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1860645/.
1 2 3 4 5 Sherrid, M. V.; Shetty, A; Winson, G; Kim, B; Musat, D; Alviar, C. L.; Homel, P; Balaram, S. K. et al. (2013). “Treatment of obstructive hypertrophic cardiomyopathy symptoms and gradient resistant to first-line therapy with β-blockade or verapamil”. Circulation: Heart Failure 6 (4): 694–702. doi:10.1161/CIRCHEARTFAILURE.
J Am Coll Cardiol 58 (25): e212–260. (2011). doi:10.1016/j.jacc.2011.06.011. PMID 22075469.
↑ Kajimoto K, Imai T, Minami Y, Kasanuki H. Comparison of acute reduction in left ventricular outflow tract pressure gradient in obstructive hypertrophic cardiomyopathy by disopyramide versus pilsicainide versus cibenzoline. Am J Cardiol. 2010;106:1307-1312
↑ “Disopyramide-pyridostigmine interaction: Selective reversal of anticholinergic symptoms with preservation of antiarrhythmic effect”. J Am Coll Cardiol 10 (3): 633–641. (1987). doi:10.1016/s0735-1097(87)80207-3.
↑ Sherrid MV, Arabadjian M. A primer of disopyramide treatment of obstructive hypertrophic cardiomyopathy. Prog Cardiovasc Dis. 2012;54:483-492